Sign In
Buy CTXR
$0.570
-0.0620 (-9.81%)
At Close: Jul 31, 2026
Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
08:00am, Friday, 13'th Feb 2026
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Onco
Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™
08:00am, Friday, 13'th Feb 2026
Company reports $3.9 million in revenue generated from initial sales in December 2025 and provides first fiscal quarter 2026 financial results CRANFORD, N.J., Feb. 13, 2026 /PRNewswire/ -- Citius Pha
Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
08:00am, Wednesday, 11'th Feb 2026
Third international distribution agreement further advances global access strategy with major markets in Europe CRANFORD, N.J., Feb. 11, 2026 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology")
PainReform (NASDAQ:PRFX) vs. Citius Pharmaceuticals (NASDAQ:CTXR) Financial Comparison
02:22am, Saturday, 10'th Jan 2026
PainReform (NASDAQ: PRFX - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the t
Analyzing Citius Pharmaceuticals (NASDAQ:CTXR) and Relmada Therapeutics (NASDAQ:RLMD)
02:34am, Monday, 05'th Jan 2026
Relmada Therapeutics (NASDAQ: RLMD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the better business? We will compar
(Editor's note: The future prices of benchmark tracking ETFs and headline were updated in the story.) U.S. stock futures slipped on Wednesday after Tuesday's higher close. Futures of major benchmark i
Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
04:30pm, Tuesday, 23'rd Dec 2025
Subsidiary, Citius Oncology, launches cancer immunotherapy, LYMPHIR™, in the U.S. in December 2025 CRANFORD, N.J. , Dec. 23, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the
Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
04:30pm, Tuesday, 23'rd Dec 2025
Cancer Immunotherapy, LYMPHIR™, launched in the U.S. in December 2025 Completed $36 million in strategic financings, of which $18 million was via private placement and concurrent registered direct o
Tonix Pharmaceuticals (NASDAQ:TNXP) & Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Contrast
02:00am, Friday, 19'th Dec 2025
Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will con
CRANFORD, N.J. , Dec. 10, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharm
Proceeds strengthen cash position and support commercial launch of LYMPHIR™, a novel cancer immunotherapy for cutaneous T-cell lymphoma (CTCL) CRANFORD, N.J. , Dec. 9, 2025 /PRNewswire/ -- Citius On
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
08:37am, Thursday, 04'th Dec 2025
Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE LYMPHIR international availability extends to 1
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
12:00pm, Monday, 01'st Dec 2025
LYMPHIR now available nationwide CRANFORD, N.J. , Dec. 1, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc.
Ironwood Pharmaceuticals (NASDAQ:IRWD) versus Citius Pharmaceuticals (NASDAQ:CTXR) Critical Analysis
03:16am, Saturday, 29'th Nov 2025
Ironwood Pharmaceuticals (NASDAQ: IRWD - Get Free Report) and Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will com
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
08:00am, Tuesday, 25'th Nov 2025
Citius Oncology's LYMPHIR™ exhibit will be located at Booth #265 LYMPHIR launch on track for Q4 2025 CRANFORD, N.J. , Nov. 25, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq:
